anti-HBV infection program (Taigen Biotechnology)

N/A

Report date: 2025/03/14 16:32:01
NME

Base Information

Drug Nameanti-HBV infection program (Taigen Biotechnology)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTaiGen Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiGen Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A